Identification of SPRYD4 as a tumour suppressor predicts prognosis and correlates with immune infiltration in cholangiocarcinoma

Cholangiocarcinoma (CCA) is an aggressive solid tumour with a 5-year survival rate ranging from 7% to 20%. It is, therefore, urgent to identify novel biomarkers and therapeutic targets to improve the outcomes of patients with CCA. SPRY-domain containing protein 4 (SPRYD4) contains SPRY domains that...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Zuyi, Xie, Tiange, Sun, Jia, Yu, Jianchun, Huang, Shanzhou, Zhou, Qi, Li, Binglu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161465/
https://www.ncbi.nlm.nih.gov/pubmed/37142983
http://dx.doi.org/10.1186/s12885-023-10810-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161465/
https://www.ncbi.nlm.nih.gov/pubmed/37142983
http://dx.doi.org/10.1186/s12885-023-10810-9

Ejemplares similares